ArticleDiscover oncology2026
LncRNA TAF1A-AS1 regulates the progression in hepatocellular carcinoma by targeting miR-664b-3p/USP22 axis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLong non-coding RNAs (lncRNAs) play an important regulatory role in tumorigenesis and progression. However the role of TAF1A-AS1 in hepatocellular carcinoma (HCC) remains unclear. Therefore, this study aimed to clarify the specific role of TAF1A-AS1 in regulating tumorigenesis and progression of HCC.
methodsQuantitative real-time PCR (qRT-PCR) was used to determine the expression of TAF1A-AS1, miR-664b-3p and USP22 in tissue samples and cell lines. Functional assays, including Cell Counting Kit-8 (CCK-8) assay, colony formation assay, transwell assays and chemoresistance assay, were performed to study the effects of TAF1A-AS1 in HCC cells. Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) were performed to examine the interaction between TAF1A-AS1 and miR-664b-3p, as well as between miR-664b-3p and USP22. A nude mouse xenograft model was established for the in vivo experiments.
resultsTAF1A-AS1 was remarkably upregulated in HCC tissues, and patients with high TAF1A-AS1 expression had poorer prognosis. Both in vitro and in vivo experiments showed that TAF1A-AS1 promoted the proliferation, invasion and tumorigenicity of HCC cells. Furthermore, mechanism study revealed that TAF1A-AS1 served as a sponge of miR-664b-3p, and USP22 was identified as a downstream target of miR-664b-3p. Additionally, TAF1A-AS1 affected HCC cells sensitivity to sorafenib and activated mTOR signaling through USP22.
conclusionOur study demonstrated that TAF1A-AS1 regulated the progression of HCC by sponging miR-664b-3p to activate USP22. These results suggest that TAF1A-AS1 could be a novel HCC prognostic biomarker and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.